{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:27:58Z","timestamp":1780068478348,"version":"3.54.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272695"],"award-info":[{"award-number":["82272695"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LZ23H160004"],"award-info":[{"award-number":["LZ23H160004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41417-025-00904-w","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T16:21:18Z","timestamp":1744906878000},"page":"678-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The activated tyrosine kinase ACK1 by multiple receptor tyrosine kinases promotes proliferation and invasion of mesothelioma via regulation of PI3K\/AKT\/mTOR and RAF\/MAPK signaling pathways"],"prefix":"10.1038","volume":"32","author":[{"given":"Yue","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuihao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-9442","authenticated-orcid":false,"given":"Wen-Bin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA Cancer J Clin"},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1593\/neo.101156","volume":"13","author":"WB Ou","year":"2011","unstructured":"Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia. 2011;13:12\u201322.","journal-title":"Neoplasia"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","volume":"6","author":"M Brevet","year":"2011","unstructured":"Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 2011;6:864\u201374.","journal-title":"J Thorac Oncol"},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/jpm12121993","volume":"12","author":"F Zito Marino","year":"2022","unstructured":"Zito Marino F, Della Corte CM, Ciaramella V, Erra S, Ronchi A, Fiorelli A, et al. AXL and MET tyrosine kinase receptors co-expression as a potential therapeutic target in malignant pleural mesothelioma. J Pers Med. 2022;12:1993.","journal-title":"J Pers Med"},{"key":"904_CR5","first-page":"5242","volume":"62","author":"PA J\u00e4nne","year":"2002","unstructured":"J\u00e4nne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62:5242\u20137.","journal-title":"Cancer Res"},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66:352\u201361.","journal-title":"Cancer Res"},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/onc.2010.555","volume":"30","author":"WB Ou","year":"2011","unstructured":"Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, et al. AXL regulates mesothelioma proliferation and invasiveness. Oncogene. 2011;30:1643\u201352.","journal-title":"Oncogene"},{"key":"904_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0159-6","volume":"8","author":"YC Tan","year":"2019","unstructured":"Tan YC, Srivastava S, Won BM, Kanteti R, Arif Q, Husain AN, et al. EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis. 2019;8:49.","journal-title":"Oncogenesis"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/bjc.2016.331","volume":"115","author":"WB Ou","year":"2016","unstructured":"Ou WB, Lu M, Eilers G, Li H, Ding J, Meng X, et al. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer. 2016;115:1253\u201363.","journal-title":"Br J Cancer"},{"key":"904_CR10","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","volume":"110","author":"S Zhou","year":"2014","unstructured":"Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma. Br J Cancer. 2014;110:2479\u201388.","journal-title":"Br J Cancer"},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jcp.22162","volume":"224","author":"K Mahajan","year":"2010","unstructured":"Mahajan K, Mahajan NP. Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol. 2010;224:327\u201333.","journal-title":"J Cell Physiol"},{"key":"904_CR12","doi-asserted-by":"publisher","first-page":"22112","DOI":"10.1074\/jbc.M112.357384","volume":"287","author":"K Mahajan","year":"2012","unstructured":"Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem. 2012;287:22112\u201322.","journal-title":"J Biol Chem"},{"key":"904_CR13","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/ijc.29234","volume":"136","author":"J Zhang","year":"2015","unstructured":"Zhang J, Chen T, Mao Q, Lin J, Jia J, Li S, et al. PDGFR-\u03b2-activated ACK1-AKT signaling promotes glioma tumorigenesis. Int J Cancer. 2015;136:1769\u201380.","journal-title":"Int J Cancer"},{"key":"904_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/cbf.3522","volume":"38","author":"B Wang","year":"2020","unstructured":"Wang B, Song K, Chen L, Su H, Gao L, Liu J, et al. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN\/AKT\/mTOR pathway. Cell Biochem Funct. 2020;38:642\u201350.","journal-title":"Cell Biochem Funct"},{"key":"904_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166690","volume":"1869","author":"W He","year":"2023","unstructured":"He W, Xu L, Ding J, Song L, Yang W, Klooster I, et al. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166690.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"904_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2020.09.023","volume":"150","author":"J Gu","year":"2020","unstructured":"Gu J, Qian L, Zhang G, Mahajan NP, Owonikoko TK, Ramalingam SS, et al. Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung Cancer. 2020;150:26\u201335.","journal-title":"Lung Cancer"},{"key":"904_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01202-9","volume":"19","author":"T Zhang","year":"2020","unstructured":"Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19:90.","journal-title":"Mol Cancer"},{"key":"904_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763\u201372.","journal-title":"Lancet Oncol"},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25\u201330.","journal-title":"J Clin Oncol"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood.V74.3.940.940","volume":"74","author":"GD Demetri","year":"1989","unstructured":"Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989;74:940\u20136.","journal-title":"Blood"},{"key":"904_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0046-8177(82)80083-X","volume":"13","author":"AM Behbehani","year":"1982","unstructured":"Behbehani AM, Hunter WJ, Chapman AL, Lin F. Studies of a human mesothelioma. Hum Pathol. 1982;13:862\u20136.","journal-title":"Hum Pathol"},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov"},{"key":"904_CR23","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1021\/acs.jmedchem.3c01934","volume":"67","author":"A Wang","year":"2024","unstructured":"Wang A, Shuai W, Wu C, Pei J, Yang P, Wang X, et al. Design, synthesis, and biological evaluation of dual inhibitors of EGFR(L858R\/T790M) \/ACK1 to overcome osimertinib resistance in non small cell lung cancers. J Med Chem. 2024;67:2777\u2013801.","journal-title":"J Med Chem"},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tips.2024.11.006","volume":"46","author":"D Sridaran","year":"2025","unstructured":"Sridaran D, Mahajan NP. ACK1\/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics. Trends Pharm Sci. 2025;46:62\u201377.","journal-title":"Trends Pharm Sci"},{"key":"904_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34724-5","volume":"13","author":"D Sridaran","year":"2022","unstructured":"Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, et al. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun. 2022;13:6929.","journal-title":"Nat Commun"},{"key":"904_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jid.2020.06.041","volume":"141","author":"Z Ji","year":"2021","unstructured":"Ji Z, Njauw CN, Guhan S, Kumar R, Reddy B, Rajadurai A, et al. Loss of ACK1 Upregulates EGFR and mediates resistance to BRAF inhibition. J Invest Dermatol. 2021;141:1317\u201324.","journal-title":"J Invest Dermatol"},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/s41388-023-02747-x","volume":"42","author":"M Sawant","year":"2023","unstructured":"Sawant M, Wilson A, Sridaran D, Mahajan K, O\u2019Conor CJ, Hagemann IS, et al. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4\/6 inhibitor. Oncogene. 2023;42:2263\u201377.","journal-title":"Oncogene"},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ajpath.2011.12.028","volume":"180","author":"K Mahajan","year":"2012","unstructured":"Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ, et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol. 2012;180:1386\u201393.","journal-title":"Am J Pathol"},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"40622","DOI":"10.18632\/oncotarget.5872","volume":"6","author":"X Lei","year":"2015","unstructured":"Lei X, Li YF, Chen GD, Ou DP, Qiu XX, Zuo CH, et al. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget. 2015;6:40622\u201341.","journal-title":"Oncotarget"},{"key":"904_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","volume":"31","author":"K Mahajan","year":"2017","unstructured":"Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, et al. ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer cell. 2017;31:790\u2013803.","journal-title":"Cancer cell"},{"key":"904_CR31","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.18632\/oncotarget.13579","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, Zahari MS, Renuse S, Kelkar DS, Barbhuiya MA, Rojas PL, et al. The non-receptor tyrosine kinase TNK2\/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget. 2017;8:2971\u201383.","journal-title":"Oncotarget"},{"key":"904_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1677\/ERC-09-0038","volume":"16","author":"M Lupien","year":"2009","unstructured":"Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr Relat Cancer. 2009;16:381\u20139.","journal-title":"Endocr Relat Cancer"},{"key":"904_CR33","first-page":"106","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106\u201316.","journal-title":"Cancer Biol Med"},{"key":"904_CR34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/14767058.2018.1515196","volume":"33","author":"Y Liu","year":"2020","unstructured":"Liu Y, Shan N, Yuan Y, Tan B, He C, Tong C, et al. Knockdown of activated Cdc42-associated kinase inhibits human extravillous trophoblast migration and invasion and decreases protein expression of pho-Akt and matrix metalloproteinase. J Matern Fetal Neonatal Med. 2020;33:1125\u201333.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"904_CR35","doi-asserted-by":"publisher","first-page":"28179","DOI":"10.1074\/jbc.M114.584425","volume":"289","author":"K Mahajan","year":"2014","unstructured":"Mahajan K, Lawrence HR, Lawrence NJ, Mahajan NP. ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem. 2014;289:28179\u201391.","journal-title":"J Biol Chem"},{"key":"904_CR36","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"904_CR37","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"904_CR38","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161\u201372.","journal-title":"Lancet Oncol"},{"key":"904_CR39","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato T, Sekido Y. NF2\/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19:988.","journal-title":"Int J Mol Sci"},{"key":"904_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","volume":"22","author":"BCJ Cho","year":"2021","unstructured":"Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22:190\u20137.","journal-title":"Lancet Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00904-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00904-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00904-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T22:02:27Z","timestamp":1750629747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00904-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00904-w","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with recognized ethical guidelines (U.S. Common Rule). The research involving human participants was approved by the Institutional Review Board of Brigham and Women\u2019s Hospital (Approval No. 2010P002888), and the patients provided their written informed consent to participate in this study. For animal experiments, approval was obtained from the Animal Ethics Committee of Zhejiang Sci-Tech University (Approval No. 20240224-08). All animal care and experimental procedures adhered to the guidelines outlined in the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}